Alivum / Ravenmac Pharma - LARVOL DELTA

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: First Affiliated Hospital of Ningbo University

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

"Fantastic commentary citing real world obstacles to realizing potential for #bamalivumab & other largely unattainable treatments for #COVID19 . @overton_edgar @msaagmd @JoHofmann2 @SonyaHeathMD @NerdmannID" (@DrJeanneM)

Clinical • Real-World Evidence • Infectious Disease • Novel Coronavirus Disease